白蛋白结合型紫杉醇联合卡铂对比吉西他滨联合卡铂一线治疗晚期鳞状细胞肺癌的随机II期临床试验(C-TONG1002)
这项多中心随机II期试验比较白蛋白结合型紫杉醇联合卡铂(nab-PC)与吉西他滨联合卡铂(GC)一线治疗晚期鳞状细胞肺癌的疗效与安全性。127例患者入组(nab-PC组62例,GC组65例),主要终点客观缓解率(ORR)两组无统计学差异(42% vs 27%,P>0.05)。中位随访14.5个月,两组无进展生存期(PFS)和总生存期(OS)均无差异。nab-PC组生活质量改善更明显,GC组第2周期后剂量下调更多(27% vs 12%,P<0.05)。
要点
- nab-PC与GC一线治疗晚期鳞状细胞肺癌的ORR分别为42%和27%,差异无统计学意义(P>0.05)。
- 两组PFS(6.7 vs 5.8个月,HR 0.75,P=0.143)和OS(11.6 vs 14.4个月,HR 0.92,P=0.846)均无差异。
- nab-PC组生活质量改善优于GC组(P<0.05),GC组第2周期后剂量下调更多(27% vs 12%,P<0.05)。
核心结论
- 一线nab-PC与GC在晚期鳞状细胞肺癌患者中具有相同的缓解率、PFS和OS。
- nab-PC在生活质量改善方面优于GC。
研究设计与样本
- 多中心随机II期临床试验,比较nab-PC与GC用于既往未治疗的晚期鳞状细胞肺癌患者。
- 主要终点为客观缓解率(ORR),同时分析PFS、OS、治疗相关不良事件和生活质量(QoL)。
- 共127例患者可评估(nab-PC组62例,GC组65例)。
主要发现
- nab-PC组ORR为42%,GC组为27%,差异无统计学意义(P>0.05)。
- 中位随访14.5个月,两组PFS分别为6.7个月和5.8个月(HR 0.75,P=0.143)。
- 两组OS分别为11.6个月和14.4个月(HR 0.92,P=0.846)。
- GC组第2周期后剂量下调发生率27%,nab-PC组为12%(P<0.05)。
- 采用试验结局指数测量的生活质量改善在nab-PC组显著优于GC组(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nab-paclitaxel/carboplatin (nab-PC) and gemcitabine/carboplatin (GC) are the standard first-line chemotherapy in non-small cell lung carcinoma. Up to now, there is no head to head trial to compare nab-PC with GC in advanced squamous cell lung carcinoma. PATIENTS AND METHODS: A multicentre randomised phase II trial was performed to compare the efficacy and safety for nab-PC with GC in previously untreated patients with advanced squamous cell lung carcinoma. The primary end-point was objective response rate (ORR). Progression-free survival (PFS), overall survival (OS), treatment-related adverse events and quality of life (QoL) were also analysed. RESULTS: Totally 127 participants were eligible for this study (62/65 nab-PC/GC). Nab-PC has higher ORR than GC without statistical significance (42% versus 27%, P > 0.05). After a median follow-up of 14.5 months, both PFS and OS had no difference between the two arms (6.7 versus 5.8 months, hazard ratio [HR] 0.75, P = 0.143; 11.6 versus 14.4 months, HR 0.92, P = 0.846). Both regimens were well tolerated; however, more dose reduction occurred after cycle 2 in GC (27%) than in nab-PC (12%) (P < 0.05). Significant QoL improvement measured by trial outcome index was seen in nab-PC than in GC (P < 0.05). CONCLUSIONS: The first-line nab-PC and GC had the same response, PFS, and OS in patients with advanced squamous cell lung carcinoma. Nab-PCM has advantage over GC in QoL improvement. TRIAL REGISTRATION NUMBER: NCT01236716.
引用
- Wang Z, Huang C, Yang JJ, et al. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). Eur J Cancer. 2019. PMID: 30739019. doi:10.1016/j.ejca.2019.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。